MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP announced an investigation into MapLight Therapeutics regarding potential securities law violations on behalf of investors. The investigation stems from a 65% share price drop on July 27, 2026, after Phase 2 results for its schizophrenia drug candidate showed the primary endpoint was not statistically significant.
Key figures
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.